Cargando…

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review

With the increasing clinical potential of tumor immunotherapy, more and more clinical trials are undergoing with immune checkpoint inhibitors (ICIs). Immune checkpoints (ICs) have been identified as crucial regulators of the immune response and have improved ICIs-inhibitor therapeutic strategies. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yu, Chen, Peixin, Wang, Hao, Wu, Shengyu, Zhao, Sha, He, Yayi, Zhou, Caicun, Hirsch, Fred R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947413/ https://www.ncbi.nlm.nih.gov/pubmed/33718041 http://dx.doi.org/10.21037/tlcr-20-1019

Ejemplares similares

Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
por: Guo, Haoyue, et al.
Publicado: (2020)

sLAG-3 in non-small-cell lung cancer patients’ serum
por: He, Yayi, et al.
Publicado: (2018)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
por: He, Yayi, et al.
Publicado: (2016)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

CD39: the potential target in small cell lung cancer
por: Chen, Shanhao, et al.
Publicado: (2020)

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Non‐small cell lung cancer in China
por: Chen, Peixin, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure
por: Chen, Peixin, et al.
Publicado: (2020)

KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
por: He, Yayi, et al.
Publicado: (2016)

The application of artificial intelligence in lung cancer: a narrative review
por: Zhang, Huixian, et al.
Publicado: (2021)

Current progress and mechanisms of bone metastasis in lung cancer: a narrative review
por: Wu, Shengyu, et al.
Publicado: (2021)

mRNA Network: Solution for Tracking Chemotherapy Insensitivity in Small-Cell Lung Cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review
por: Viscardi, Giuseppe, et al.
Publicado: (2022)

Risk factors for nicotine dependence in Chinese patients with lung cancer
por: Gu, Fen, et al.
Publicado: (2018)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

A narrative review of tumor heterogeneity and challenges to tumor drug therapy
por: Zhu, Liang, et al.
Publicado: (2021)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review
por: Wu, Yan, et al.
Publicado: (2020)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer
por: Dai, Jiawei, et al.
Publicado: (2021)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Treatment of spine metastases in cancer: a review
por: Chen, Yu, et al.
Publicado: (2019)

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
por: Zielinski, C., et al.
Publicado: (2013)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
por: He, Yayi, et al.
Publicado: (2017)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2021)

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
por: Zhao, Yu, et al.
Publicado: (2023)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0a9op93mtcoulnetoqcptagfrs